Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications association between tumor necrosis factor inhibitor tnfi therapy changes c reactive
… payers. Objection Handlers Objection handlers are for reactive use when your teams are challenged by payers and … can conduct interactive workshops to maximize engagement between attendees and ensure active learning. Your Value …
… Longitudinal Modeling Approaches to Assess Association Between Two Clinical Outcomes Assessments Bintu Sherif, MS … modeling approaches to assess the association between changes in 2 clinical outcome assessments. Ther Innov Regul …
… research is needed to further explain the variations between states. However, results from this recent study …
… In the end, studies showed that a similar risk exists between FORTEO® users and their comparators, or the general …
… ICER’s 2023 Value Assessment Framework Updates: How Might Changes Impact Pharmaceutical Companies? Share on: July 28, … studies that support alternative value of the new therapy For long-term cost-effectiveness analyses, ICER … approach. The new method uses the published relationship between patients’ utility score and how they use their time …
… patients with HR+/HER2– metastatic breast cancer. Links to publications: Goyal RK, Chen H, Abughosh SM, Holmes HM, … CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the …
… Investigating the Relationship Between Suboptimal Meningococcal Immunization and Health … race on MenACWY vaccine uptake was likely captured by the association of race with poverty, geographic area, and access … adults in the United States: a systematic review. Masaquel C, Schley K, Wright K, Mauskopf J, Parrish RA, Presa JV, …
… Lymphocytic Leukemia Time trends in frontline systemic therapy utilization for chronic lymphocytic leukemia in the … the use of a first-in-class Bruton’s tyrosine kinase inhibitor, ibrutinib, increased sharply to 25.8% by early … increase in the uptake of ibrutinib as the frontline therapy for CLL in the US. Additional novel agents are on the …
… – Member of the Program Committee of Drug Information Association (DIA) , Adjunct Professor, Epidemiology, …
… in overabundance of growth hormone and insulin-like growth factor-1. This hormonal excess results in tissue growth, including changes to facial features. As the condition progresses, many … experience lethargy, headaches, and joint pain alongside changes to their soft tissue. People with acromegaly may also …